Medical International Technology Signs Distribution Agreements and Receives Initial Sales Commitments Valued at More Than $3.6 Million over Three Years.

Business Editors/Health/Medical Writers

DENVER--(BUSINESS WIRE)--June 3, 2003

Medical International Technology, Inc. (OTCBB: MDIR), a developer and marketer of patented needle-free jet injectors for human and animal inoculation, today announced that its MIT Canada subsidiary has signed two new distribution agreements for its AGRO-JET needle-free injectors for animals with distributors in Denmark and South Korea, and received initial sales commitments from three previously announced distributors in Taiwan, Greece and the Czech Republic for a total value of nearly U.S. $3.7 million over a three-year period.

Danemark Unitron Scandinavia A/S has been granted exclusive distribution rights for MIT's AGRO-JET needle-free injectors in Denmark, Norway, Sweden, Holland and Finland. The value of the three-year agreement is estimated at U.S. $2.4 million. Danemark Unitron, based in Torring, Denmark, sells to 25 countries around the world. It has more than 20 years of experience as a leader in the field of farm equipment and specializes in artificial insemination and products aimed at the swine industry.

MIT also signed a distribution agreement with Song Kang Co., Ltd. in Seoul, South Korea for exclusive distribution rights in that country, valued at U.S. $280,000 over three years. Song Kang, with a 70% share of the South Korean pig breeding import market, is the country's leading supplier of agricultural tools and equipment, including artificial insemination, laboratory and science supplies.

MIT also announced that it has finalized an agreement announced this past March with Sevaron Ltd., a veterinary products distributor in Brno, Czechoslovakia, for distribution rights for the AGRO-JET in that country, with a three-year value estimated at approximately U.S. $175,000. It also received sales commitments valued at approximately U.S. $550,000 over three years from its distributor in Taiwan, for the country's poultry industry, Acevet International Marketing Co., Ltd., signed in March, as well as three-year sales commitments valued at approximately U.S. $250,000 from its distributor in Greece, Tetoros Bros., also signed in March.

"As a result of an intense international marketing effort, Medical International Technology is beginning to see a rapid acceleration of interest in its line of patented AGRO-JET needle-free injectors for animals as evidenced by the 8 agreements we have entered into during the last 6 months for distribution of our products in 10 countries around the world, valued at U.S. $7.2 million over the next 3 years," stated Karim Menassa, President and Chief Executive Officer of MIT.

MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations. MIT CANADA has just introduced several models of the Agro-Jet, a needle-free jet injector for different niches in animal applications, and the Med-Jet, for human mass vaccinations.

This press release contains certain "forward-looking" statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995 that involves a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors that may be identified from time to time in the Company's public announcements.